{"seq": 1, "variant": "treatment", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nRecommended workflow:\n  pm quick       Search + fetch + parse in one command (RECOMMENDED)\n  pm filter      Filter JSONL articles by year, journal, author, etc.\n\nAll commands:\n  quick       Search + fetch + parse in one command (RECOMMENDED)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  init        Initialize audit trail and cache (.pm/)\n\nExamples:\n  pm quick \"CRISPR cancer\" --max 100 > results.jsonl\n  pm filter --year 2024 --has-abstract < results.jsonl\n\nTip: save results to a file so you can reuse them without re-searching:\n  pm quick \"my query\" > results.jsonl\n  pm filter --year 2024 < results.jsonl\n  pm filter --has-doi < results.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.435, "ts": 1771589789.7867477}
{"seq": 2, "variant": "treatment", "cmd": "pm quick personalized dosimetry Lu-PSMA radioligand therapy prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 1.495, "ts": 1771589799.683861}
{"seq": 3, "variant": "treatment", "cmd": "pm quick personalized dosimetry Lu-PSMA radioligand therapy prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 1.248, "ts": 1771589937.712279}
